Adcomm says Intercept's rare liver disease drug should not get full approval
An FDA advisory committee recommended against full approval for Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva by a 13-1 vote, concluding that confirmatory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
